Biodesix (BDSX) Stock Forecast, Price Target & Predictions
BDSX Stock Forecast
Biodesix stock forecast is as follows: an average price target of $3.00 (represents a 69.49% upside from BDSX’s last price of $1.77) and a rating consensus of 'Buy', based on 2 wall street analysts offering a 1-year stock forecast.
BDSX Price Target
The average price target for Biodesix (BDSX) is $3.00 based on 1-year price targets from 2 Wall Street analysts in the past 3 months, with a price target range of $3.00 to $3.00. This represents a potential 69.49% upside from BDSX's last price of $1.77.
BDSX Analyst Ratings
According to 2 Wall Street analysts, Biodesix's rating consensus is 'Buy'. The analyst rating breakdown for BDSX stock is 0 'Strong Buy' (0.00%), 2 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
Biodesix Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 26, 2024 | Bill Bonello | Craig-Hallum | $3.00 | $1.68 | 78.57% | 69.49% |
The latest Biodesix stock forecast, released on Jul 26, 2024 by Bill Bonello from Craig-Hallum, set a price target of $3.00, which represents a 78.57% increase from the stock price at the time of the forecast ($1.68), and a 69.49% increase from BDSX last price ($1.77).
Biodesix Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 1 | 1 |
| Avg Price Target | - | $3.00 | $3.00 |
| Last Closing Price | $1.77 | $1.77 | $1.77 |
| Upside/Downside | -100.00% | 69.49% | 69.49% |
In the current month, the average price target of Biodesix stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to Biodesix's last price of $1.77. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 26, 2024 | Craig-Hallum | - | Buy | Initialise |
| May 13, 2024 | Cowen & Co. | - | Buy | Initialise |
Biodesix's last stock rating was published by Craig-Hallum on Jul 26, 2024. The company Initialise its BDSX rating from "null" to "Buy".
Biodesix Financial Forecast
Biodesix Revenue Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | $13.49M | $11.87M | $9.06M | $9.61M | $11.11M | $10.95M | $6.55M | $7.22M | $6.53M | $11.88M | $28.87M | $27.03M | $9.19M |
| Avg Forecast | $24.75M | $23.55M | $22.45M | $20.38M | $19.84M | $18.68M | $16.13M | $14.18M | $15.62M | $14.12M | $11.67M | $8.71M | $10.77M | $10.15M | $8.83M | $6.47M | $7.29M | $6.15M | $20.58M | $26.23M | $15.47M | $8.66M |
| High Forecast | $25.04M | $23.83M | $22.71M | $20.61M | $20.07M | $19.03M | $16.32M | $14.35M | $15.77M | $14.29M | $11.81M | $8.81M | $10.90M | $10.27M | $8.96M | $6.57M | $7.40M | $6.25M | $20.90M | $26.63M | $15.70M | $8.79M |
| Low Forecast | $23.98M | $22.82M | $21.75M | $19.74M | $19.22M | $18.33M | $15.63M | $13.74M | $15.46M | $13.68M | $11.31M | $8.44M | $10.44M | $9.84M | $8.60M | $6.30M | $7.11M | $6.00M | $20.07M | $25.57M | $15.08M | $8.44M |
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.96% | 1.02% | 1.04% | 0.89% | 1.09% | 1.24% | 1.01% | 0.99% | 1.06% | 0.58% | 1.10% | 1.75% | 1.06% |
Biodesix's average Quarter revenue forecast for Dec 23 based on 2 analysts is $15.62M, with a low forecast of $15.46M, and a high forecast of $15.77M. BDSX's average Quarter revenue forecast represents a 15.75% increase compared to the company's last Quarter revenue of $13.49M (Sep 23).
Biodesix EBITDA Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| EBITDA | - | - | - | - | - | - | - | - | - | $-7.17M | $-10.93M | $-16.35M | $-13.89M | $-8.94M | $-10.18M | $-13.18M | $-19.95M | $-9.17M | $-9.81M | $-5.56M | $-3.10M | $3.43M |
| Avg Forecast | $-18.95M | $-18.03M | $-17.19M | $-15.60M | $-15.19M | $-14.30M | $-12.36M | $-10.86M | $-11.96M | $-10.81M | $-8.94M | $-6.67M | $-8.25M | $-11.56M | $-6.76M | $-9.95M | $-5.58M | $-4.71M | $-15.76M | $-3.60M | $-11.84M | $-6.63M |
| High Forecast | $-18.36M | $-17.47M | $-16.66M | $-15.12M | $-14.72M | $-14.03M | $-11.97M | $-10.52M | $-11.84M | $-10.48M | $-8.66M | $-6.46M | $-7.99M | $-9.24M | $-6.59M | $-7.96M | $-5.44M | $-4.59M | $-15.37M | $-2.88M | $-11.55M | $-6.47M |
| Low Forecast | $-19.18M | $-18.25M | $-17.39M | $-15.79M | $-15.37M | $-14.58M | $-12.50M | $-10.99M | $-12.08M | $-10.94M | $-9.04M | $-6.75M | $-8.35M | $-13.87M | $-6.86M | $-11.93M | $-5.67M | $-4.78M | $-16.00M | $-4.32M | $-12.02M | $-6.73M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.66% | 1.22% | 2.45% | 1.68% | 0.77% | 1.51% | 1.33% | 3.57% | 1.95% | 0.62% | 1.55% | 0.26% | -0.52% |
1 analysts predict BDSX's average Quarter EBITDA for Dec 20 to be $-11.84M, with a high of $-11.55M and a low of $-12.02M. This is -445.06% lower than Biodesix's previous annual EBITDA (Sep 20) of $3.43M.
Biodesix Net Income Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| Net Income | - | - | - | - | - | - | - | - | - | $-10.95M | $-13.36M | $-17.12M | $-26.79M | $-16.79M | $-20.02M | $-16.79M | $-5.76M | $-11.51M | $-11.40M | $-6.96M | $-4.53M | $-8.85K |
| Avg Forecast | $-5.72M | $-6.99M | $-7.31M | $-8.58M | $-8.14M | $-9.16M | $-11.71M | $-18.07M | $-13.87M | $-18.65M | $-26.23M | $-30.10M | $-35.30M | $-14.51M | $-59.13M | $-11.69M | $-62.56M | $-60.72M | $-36.46M | $-4.50M | $-51.10M | $-36.46M |
| High Forecast | $-5.49M | $-6.71M | $-7.02M | $-8.24M | $-7.81M | $-8.79M | $-11.23M | $-17.34M | $-10.09M | $-17.90M | $-25.17M | $-28.88M | $-33.87M | $-11.61M | $-57.21M | $-9.35M | $-60.52M | $-58.75M | $-35.27M | $-3.60M | $-49.44M | $-35.27M |
| Low Forecast | $-5.81M | $-7.10M | $-7.42M | $-8.72M | $-8.26M | $-9.30M | $-11.89M | $-18.35M | $-16.39M | $-18.94M | $-26.63M | $-30.56M | $-35.84M | $-17.41M | $-60.31M | $-14.03M | $-63.81M | $-61.93M | $-37.18M | $-5.41M | $-52.12M | $-37.18M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.59% | 0.51% | 0.57% | 0.76% | 1.16% | 0.34% | 1.44% | 0.09% | 0.19% | 0.31% | 1.55% | 0.09% | 0.00% |
Biodesix's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. BDSX's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).
Biodesix SG&A Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| SG&A | - | - | - | - | - | - | - | - | - | $15.50M | $16.65M | $18.99M | $16.63M | $15.11M | $15.23M | $14.49M | $13.56M | $13.61M | $11.43M | $11.93M | $39.04M | $7.88M |
| Avg Forecast | $29.02M | $27.61M | $26.32M | $23.89M | $23.26M | $21.90M | $18.92M | $16.63M | $18.31M | $16.55M | $13.69M | $10.22M | $12.63M | $11.91M | $10.35M | $7.58M | $8.55M | $7.22M | $24.13M | $7.72M | $18.13M | $10.15M |
| High Forecast | $29.36M | $27.94M | $26.63M | $24.17M | $23.54M | $22.32M | $19.14M | $16.82M | $18.50M | $16.75M | $13.85M | $10.34M | $12.78M | $12.05M | $10.51M | $7.70M | $8.68M | $7.33M | $24.50M | $9.26M | $18.41M | $10.31M |
| Low Forecast | $28.12M | $26.76M | $25.51M | $23.15M | $22.54M | $21.49M | $18.33M | $16.11M | $18.12M | $16.04M | $13.26M | $9.90M | $12.24M | $11.54M | $10.09M | $7.39M | $8.33M | $7.03M | $23.53M | $6.17M | $17.68M | $9.90M |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.94% | 1.22% | 1.86% | 1.32% | 1.27% | 1.47% | 1.91% | 1.59% | 1.89% | 0.47% | 1.55% | 2.15% | 0.78% |
Biodesix's average Quarter SG&A projection for Dec 23 is $18.31M, based on 2 Wall Street analysts, with a range of $18.12M to $18.50M. The forecast indicates a 18.16% rise compared to BDSX last annual SG&A of $15.50M (Sep 23).
Biodesix EPS Forecast
| Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jun 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 1 | 1 | 1 | 1 | 1 | 3 | 1 | 1 | 2 | 1 | 1 | 1 | - | - | - | - | 1 | 1 | 1 | 1 | 1 | 1 |
| EPS | - | - | - | - | - | - | - | - | - | $-0.14 | $-0.17 | $-0.22 | $-0.46 | $-0.42 | $-0.51 | $-0.54 | $-0.21 | $-0.41 | $-0.41 | $-0.26 | $-0.25 | $-0.00 |
| Avg Forecast | $-0.04 | $-0.06 | $-0.06 | $-0.07 | $-0.06 | $-0.07 | $-0.09 | $-0.14 | $-0.11 | $-0.15 | $-0.21 | $-0.24 | $-0.28 | $-0.33 | $-0.47 | $-0.42 | $-0.49 | $-0.48 | $-0.29 | $-0.17 | $-0.40 | $-0.29 |
| High Forecast | $-0.04 | $-0.05 | $-0.06 | $-0.06 | $-0.06 | $-0.07 | $-0.09 | $-0.14 | $-0.08 | $-0.14 | $-0.20 | $-0.23 | $-0.27 | $-0.31 | $-0.45 | $-0.41 | $-0.48 | $-0.46 | $-0.28 | $-0.17 | $-0.39 | $-0.28 |
| Low Forecast | $-0.05 | $-0.06 | $-0.06 | $-0.07 | $-0.06 | $-0.07 | $-0.09 | $-0.14 | $-0.13 | $-0.15 | $-0.21 | $-0.24 | $-0.28 | $-0.33 | $-0.47 | $-0.43 | $-0.50 | $-0.49 | $-0.29 | $-0.18 | $-0.41 | $-0.29 |
| Surprise % | - | - | - | - | - | - | - | - | - | 0.95% | 0.82% | 0.93% | 1.66% | 1.28% | 1.10% | 1.27% | 0.43% | 0.86% | 1.43% | 1.49% | 0.62% | 0.00% |
According to undefined Wall Street analysts, Biodesix's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to BDSX previous annual EPS of $NaN (undefined).
Biodesix Peer Comparison by Price Target
| Ticker | Company | Last Closing Price | Avg Price Target | Upside/Downside | Avg Rating |
|---|---|---|---|---|---|
| LMDX | LumiraDx | $0.02 | $1.50 | 7400.00% | Buy |
| ACRS | Aclaris Therapeutics | $1.18 | $25.00 | 2018.64% | Buy |
| DRIO | DarioHealth | $0.95 | $10.75 | 1031.58% | Buy |
| STIM | Neuronetics | $0.73 | $8.00 | 995.89% | Buy |
| GTH | Genetron | $4.03 | $10.00 | 148.14% | - |
| XGN | Exagen | $2.96 | $6.00 | 102.70% | Buy |
| BDSX | Biodesix | $1.77 | $3.00 | 69.49% | Buy |
| CSTL | Castle Biosciences | $31.18 | $38.00 | 21.87% | Buy |
| OLK | Olink AB (publ) | $26.08 | $21.50 | -17.56% | Hold |
BDSX Forecast FAQ
Is Biodesix a good buy?
Yes, according to 2 Wall Street analysts, Biodesix (BDSX) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 2 'Buy' recommendations, accounting for 100.00% of BDSX's total ratings.
What is BDSX's price target?
Biodesix (BDSX) average price target is $3 with a range of $3 to $3, implying a 69.49% from its last price of $1.77. The data is based on 2 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will Biodesix stock go up soon?
According to Wall Street analysts' prediction for BDSX stock, the company can go up by 69.49% (from the last price of $1.77 to the average price target of $3), up by 69.49% based on the highest stock price target, and up by 69.49% based on the lowest stock price target.
Can Biodesix stock reach $3?
BDSX's average twelve months analyst stock price target of $3 does not support the claim that Biodesix can reach $3 in the near future.
What are Biodesix's analysts' financial forecasts?
Biodesix's analysts financial forecasts for the fiscal year (Dec 2024) are as follows: average revenue is $68.84M (high $69.78M, low $66.92M), average EBITDA is $-52.713M (high $-51.249M, low $-53.437M), average net income is $-47.076M (high $-45.176M, low $-47.798M), average SG&A $80.71M (high $81.82M, low $78.47M), and average EPS is $-0.37 (high $-0.355, low $-0.376). BDSX's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $91.12M (high $92.2M, low $88.3M), average EBITDA is $-69.782M (high $-67.616M, low $-70.604M), average net income is $-28.613M (high $-27.458M, low $-29.051M), average SG&A $106.85M (high $108.11M, low $103.53M), and average EPS is $-0.225 (high $-0.216, low $-0.228).
Did the BDSX's actual financial results beat the analysts' financial forecasts?
Based on Biodesix's last annual report (Dec 2023), the company's revenue was $49.09M, which missed the average analysts forecast of $50.12M by -2.06%. Apple's EBITDA was $-41.342M, beating the average prediction of $-38.38M by 7.72%. The company's net income was $-52.146M, missing the average estimation of $-88.842M by -41.30%. Apple's SG&A was $67.39M, beating the average forecast of $58.77M by 14.67%. Lastly, the company's EPS was $-0.64, missing the average prediction of $-0.699 by -8.39%. In terms of the last quarterly report (Sep 2023), Biodesix's revenue was $13.49M, missing the average analysts' forecast of $14.12M by -4.45%. The company's EBITDA was $-7.172M, missing the average prediction of $-10.812M by -33.67%. Biodesix's net income was $-10.949M, missing the average estimation of $-18.652M by -41.30%. The company's SG&A was $15.5M, missing the average forecast of $16.55M by -6.40%. Lastly, the company's EPS was $-0.14, missing the average prediction of $-0.147 by -4.55%